LH vs MEDP
LH: Labcorp is a global leader in diagnostics and drug development services, providing the scientific insights and analytical scale necessary to advance precision medicine and clinical research. MEDP: Medpace is a mid-sized, scientifically-focused global CRO that provides full-service clinical trial management for drug and medical device development.
Side-by-side fundamentals
| Metric | LH | MEDP | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $301.17 | $578.30 | |
| Market cap as of 2026-07-31 | $25.9B | $16.5B | |
| P/E as of 2026-07-31 | 27.48 | 33.92 | LH lower |
| PEG as of 2026-07-31 | 2.76 | 2.71 | MEDP lower |
| Net margin as of 2026-07-31 | +6.7% | +17.7% | MEDP higher |
| Gross margin as of 2026-07-31 | +28.8% | +28.8% | LH higher |
| Operating margin as of 2026-07-31 | +10.2% | +21.0% | MEDP higher |
| ROE as of 2026-07-31 | +10.9% | +110.1% | MEDP higher |
| ROA as of 2026-07-31 | +5.1% | +24.8% | MEDP higher |
| Debt / equity as of 2026-07-31 | 0.73 | 0.00 | MEDP lower |
| Revenue growth (YoY) as of 2026-07-31 | +7.3% | +24.7% | MEDP higher |
| Revenue CAGR (3y) SEC XBRL | +5.6% | +20.1% | MEDP higher |
| Dividend yield as of 2026-07-31 | +0.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | n/a | |
| Beta as of 2026-07-31 | 0.85 | 0.96 | |
| 1-year return as of 2026-07-27 close | +13.7% | +32.1% | MEDP higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.